FDA extends clearance for Xoft brachytherapy system

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The FDA has granted clearance for Xoft’s Axxent Electronic Brachytherapy System, a technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings. 

Previously cleared for accelerated treatment of early stage breast cancer, Xoft said its Axxent System is now cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. 

As a platform technology, the Axxent Electronic Brachytherapy System is designed to address a variety of oncological and non-oncological indications, according to the Sunnyvale, Calif.-based company. 

Xoft also said it is actively working to extend the use of Electronic Brachytherapy to endometrial and rectal indications, which are pending FDA clearance.